We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+54.45%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$4.6B
AUM Growth
+$1.51B
Cap. Flow
+$217M
Cap. Flow %
4.71%
Top 10 Hldgs %
30.3%
Holding
146
New
24
Increased
37
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$75.3M
2
TT icon
Trane Technologies
TT
+$39.3M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$35.1M
4
EXAS
Exact Sciences
EXAS
+$27.8M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$22.1M

Top Sells

Rank Stock Value
1
XYL icon
Xylem
XYL
+$51.6M
2
TWLO icon
Twilio
TWLO
+$48M
3
ZGNX
Zogenix, Inc.
ZGNX
+$45M
4
VRNS icon
Varonis Systems
VRNS
+$26.7M
5
SAGE
Sage Therapeutics
SAGE
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 45.14%
2 Technology 22.43%
3 Industrials 8.89%
4 Consumer Discretionary 7.31%
5 Communication Services 3.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
76
Xenon Pharmaceuticals
XENE
$6.2B
$16M 0.35%
1,274,100
– –
BLU
77
DELISTED
BELLUS Health Inc.
BLU
$15.9M 0.35%
+1,543,000
New +$15.6M
STRO icon
78
Sutro Biopharma
STRO
$411M
$15.4M 0.34%
198,598
+70,000
+54% +$6.72M
IMVT icon
79
Immunovant
IMVT
$8.11B
$15.2M 0.33%
+625,950
New +$13.4M
PHAT icon
80
Phathom Pharmaceuticals
PHAT
$720M
$14.8M 0.32%
450,000
– –
RGEN icon
81
Repligen
RGEN
$7.03B
$14.7M 0.32%
119,000
– –
DCPH
82
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.5M 0.32%
243,000
– –
CIEN icon
83
Ciena
CIEN
$52.7B
$14.5M 0.31%
+267,000
New +$13.3M
ISRG icon
84
Intuitive Surgical
ISRG
$126B
$14.2M 0.31%
75,000
– –
XLRN
85
DELISTED
Acceleron Pharma
XLRN
$13.6M 0.3%
142,900
– –
LW icon
86
Lamb Weston
LW
$7.36B
$13.3M 0.29%
208,600
-33,800
-14% -$2.04M
VRTX icon
87
Vertex Pharmaceuticals
VRTX
$122B
$13.2M 0.29%
45,500
– –
IMTX icon
88
Immatics
IMTX
$1.26B
$12.6M 0.27%
+800,000
New +$9.82M
EPIX
89
DELISTED
ESSA Pharma
EPIX
$11.8M 0.26%
2,010,169
– –
ALLK
90
DELISTED
Allakos
ALLK
$11.5M 0.25%
160,000
– –
ETNB
91
DELISTED
89bio
ETNB
$11.5M 0.25%
575,000
+225,000
+64% +$5.47M
MKC icon
92
McCormick & Company Non-Voting
MKC
$13.7B
$10.8M 0.23%
120,000
– –
EIDX
93
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$10.2M 0.22%
213,000
– –
CCXI
94
DELISTED
ChemoCentryx, Inc.
CCXI
$10.1M 0.22%
+175,000
New +$9.52M
LKFT
95
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$10.1M 0.22%
51,000
– –
XNCR icon
96
Xencor
XNCR
$1.59B
$9.72M 0.21%
300,000
– –
FENC icon
97
Fennec Pharmaceuticals
FENC
$344M
$9.35M 0.2%
1,120,000
+400,000
+56% +$2.97M
ARVN icon
98
Arvinas
ARVN
$536M
$7.71M 0.17%
230,000
– –
SNDX icon
99
Syndax Pharmaceuticals
SNDX
$1.73B
$7.3M 0.16%
492,500
+265,820
+117% +$4.05M
ADCT icon
100
ADC Therapeutics
ADCT
$141M
$7.02M 0.15%
+150,000
New +$5.69M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Eventide Asset Management held 146 positions worth $4.6B, up 49% from $3.09B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Eventide Asset Management deployed $217M of net new capital in Q2 2020, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Pliant Therapeutics: 2,838,125 shares worth $88.4M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 44% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Twilio, an estimated $48M trimmed.

  • Eventide Asset Management's largest Q2 2020 buy was Pliant Therapeutics: 2,838,125 shares worth $88.4M.
  • Eventide Asset Management added most to Trane Technologies in Q2 2020, an estimated $39.3M increase.
  • Eventide Asset Management's biggest Q2 2020 reduction was Twilio, cutting an estimated $48M.
  • Eventide Asset Management fully exited Xylem in Q2 2020, selling an estimated $51.6M.
  • Eventide Asset Management's ten largest holdings make up 30% of its $4.6B portfolio in Q2 2020.
  • Eventide Asset Management opened 24 new positions and closed 12 in Q2 2020.
  • Eventide Asset Management's portfolio value rose 49% quarter-over-quarter to $4.6B.

Based on Eventide Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.